Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- from Nov. 20, 2001 to Jan. 28, 2002
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The study was performed according to test guideline in compliance with GLP with FAT 41030 a structural analogue of FAT 41045. Both substances are very similar in their chemical structure and, as demonstrated, in a number of physicochemical properties. Therefore, this study is used for read-across thus avoiding duplicate tests.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- FAT 41030/A
- IUPAC Name:
- FAT 41030/A
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- FAT 41'030/A
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Himalayan
- Sex:
- male
- Details on test animals and environmental conditions:
- Test system Ibm: GOHI; SPF-quality guinea pigs (synonym: Himalayan spotted)
Rationale Recognized by the international guidelines as a recommended test system (e.g. OECD, EEC).
Source RCC Ud, Biotechnology & Animal Breeding Division, Wölferstrasse 4, CH-4414 Füllinsdorf / Switzerland
Number of animals for main study / pretest: 15 males / 3 males
Age at pretest startlbeginning of acclimatization period : 4 - 6 weeks
Body weight at pretest start : Pretest groups: 429 - 437 9
Body weight at beginning of acclimatization period : Control and test group 377 - 444 9
Identification By unique cage number and corresponding ear tags.
Randomization Selected by hand at time of delivery. No computer randomization.
Acclimatization: One week for the control and test group under test conditions after health examination. No acclimatization for the animals of the pretest. Only animals without any visible signs of illness were used for the study.
HUSBANDRY
Room no. 110 / RCC Ud, Füllinsdorf
Conditions: Standard Laboratory Conditions
Accommodation :Individually in Makroion type-4 cages with standard softwood bedding ("Lignocel", Schill AG, CH-4132 Muttenz).
Diet Pelleted standard Provimi Kliba 3418, batch nos. 92101 and 93/01, guinea pig breeding / maintenance diet, containing Vitamin C (Provimi Kliba AG, CH-4303 Kaiseraugst), ad Iibitum. Results of analyses for contaminants are archived at RCC Ud, Itingen.
Water : Community tap water from Füllinsdorf, ad Iibitum. Results of bacteriological, chemical and contaminant analyses are archived at RCC Ud, Itingen.
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG300
- Concentration / amount:
- Intradermal lnduction: 5%
Epidermal lnduction: 50%
Epidermal Challenge: 25%
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG300
- Concentration / amount:
- Intradermal lnduction: 5%
Epidermal lnduction: 50%
Epidermal Challenge: 25%
- No. of animals per dose:
- Intradermal Pretest: 1
Epidermal Pretest :2
Control Group :5
Test Group:10 - Details on study design:
- vehicle:
Identification Polyethylene glycol 300 (PEG 300)
Description colorless viscous liquid
Lot number 412565/1 51301
Source FLUKA Chemie GmbH, CH-9471 Buchs
Stability of vehicle Stable under storage conditions; expiration date: 10-JUL-2002
Storage conditions In the original container, at room temperature (range of 20 ± 3 ℃), away from direct sunlight.
Safety precautions Routine hygienic procedures were used to ensure the health and safety of the personnel.
The vehicle was selected based on preliminary solubility testing which was performed before the study initiation date. Therefore, the formulation trials were excluded from the statement of GLP compliance. The test item was not soluble in purified water but was readily soluble in PEG 300.
AUXILIARY COMPOUNDS: Freund's Complete Adjuvant (FCA), Physiological saline
RATIONALE
The application procedure was used to detect a possible allergenie potential of the test item applied.
READINGS AND SCORING
The scoring system was performed by visual scoring of erythema, oedema and other clinical changes of skin conditions.
SELECTION OF CONCENTRATION OF TEST ITEM FOR MAIN STUDV
Intradermal lnduction:
The 5 % concentration of test item used for the intradermal induction exposure was well-tolerated systemically and was the highest technically applicable concentration.
Epidermal lnduction: The 50 % concentration of test item used for the epidermal induction exposure was well-tolerated systemically and was the highest attainable concentration causing mild skin irritation.
Epidermal Challenge:
The 25 % concentration of the test item used for the challenge application was the maximum tested non-irritant concentration.
MAIN STUDY
1.INDUCTION
1.1 INTRADERMAL INJECTIONS I PERFORMED ON TEST DAY 1
An area of dorsal skin fram the scapular region (appraximately 6 x 8 cm) was clipped free of hair. Three pairs of intradermal injections (0.1 ml/site) were made at the border of a 4 x 6 cm area in the clipped region as folIows:
Test Group: 1) 1:1 (v/v) mixture of Freund's Complete Adjuvant and physiological saline.
2) The test item, at 5 % in PEG 300.
3) The test item at 5 % in a 1:1 (v/v) mixture of Freund's Complete Adjuvant and physiological saline.
Contra I Graup: 1) 1:1 (v/v) mixture of Freund's Complete Adjuvant and physiological saline.
2) PEG 300
3) 1:1 (w/w) mixture of PEG 300 in a 1:1 (v/v) mixture of Freund's Complete Adjuvant and physiological saline.
1.2 EPIDERMAL APPLICATIONS I PERFORMED ON TEST DAY 8
One week after the injections, the scapular area (approximately 6 x 8 cm) was again clipped and shaved free of hair prior to the application. A 2 x 4 cm patch of filter paper was saturated with the test item (50 % in PEG 300) and placed over the injection sites of the test animals.
The amount of test item preparation applied was approximately 0.3 g. The patch was covered with aluminum foil and firmly secured by an elastic piaster wrapped around the trunk of the animal and secured with impervious adhesive tape. The occlusive dressings were left in place for 48 hours. The epidermal application procedure described ensured intensive contact of the test item.
The guinea pigs of the control group were treated as described above with PEG 300 only, applied at a volume of approximately 0.3 ml.
2 CHALLENGE I PERFORMED ON TEST DAY 22
The test and control guinea pigs were challenged two weeks after the epidermal induction application and were treated in the same way.
Hair was clipped and shaved from a 5 x 5 cm area on the left and right flank of each guinea pig just prior to the application. Two patches (3 x 3 cm) of filter paper were saturated with the test item at the highest tested non-irritating concentration of 25 % (applied to the left flank) and the vehicle only (PEG 300 applied to the right flank) using the same method as for the epidermal application. The amount of test item preparation applied was approximately 0.2 g and a volume of approximately 0.2 ml was used for the vehicle. The dressings were left in place for 24 hours.
Twenty-one hours after removal of the dressing the test sites treated with the test item were depilated as described in the epidermal pretest.
OBSERVATIONS
The following observations and data were recorded during the study:
Viability / Mortality Daily from delivery of the animals to the termination of the test.
Clinical signs (systemic) Daily from delivery of the animals to the termination of the test.
Skin reactions At the times specified during the pretest, induction and challenge periods.
Body weights At pretest and acclimatization start, day 1 and termination of the test.
NECROPSY
No necropsies were performed in the animals of the control and test group sacrificed at termination of the observation period nor in the animals of the intradermal and epidermal pretest sacrificed on test day 1 of the main study.
The animals were sacrificed by intraperitoneal injection of NARCOREN (Rhöne MerieuxGmbH, D-88471 Laupheim) at a dose of at least 2.0 ml/kg body weight (equivalent to 320 mg sodium pentobarbitone/kg body weight) and discarded. - Challenge controls:
- no data
- Positive control substance(s):
- no
Results and discussion
- Positive control results:
- no data
In vivo (non-LLNA)
Results
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25% . No with. + reactions: 0.0. Total no. in groups: 10.0.
Any other information on results incl. tables
SKIN EFFECTS AFTER INTRADERMAL INDUCTION - PERFORMED ON TEST DAY 1
The expected and common findings were observed in the control and test group after the different applications using FCA intradermally. These findings consisted of erythema, oedema, necrotizing dermatitis, encrustation, exfoliation of encrustation and also red dis- coloration produced by the test item. No detailed description of the effects is given in the report as these FCA effects are well- known.
SKIN EFFECTS AFTER EPIDERMAL INDUCTION - PERFORMED ON TEST DAY 8
CONTROL GROUP
No erythematous or oedematous reaction was observed in the animals treated with PEG 300 only.
TESTGROUP
As the test item at 50 % stained the skin red, it was not possible to determine whether erythema was present or not. However, no oedema was observed. The animals were not depilated in the epidermal induction phase.
SKIN EFFECTS AFTER THE CHALLENGE - PERFORMED ON TEST DAY 22
CONTROL GROUP
No skin reactions were observed in the animals when treated with either PEG 300 only or when treated with the test item at 25 % in PEG 300. Red discoloration produced by the test item was noted directly after removal of the patch. To remove the discoloration all animals were depilated 3 hours prior to challenge reading.
TEST GROUP
No skin reactions were observed in the animals when treated with either PEG 300 only or when treated with the test item at 25 % in PEG 300. Red discoloration produced by the test item was noted directly after removal of the patch. To remove the discoloration all animals were depilated 3 hours prior to challenge reading.
VIABILITY / MORTALITY / MACROSCOPIC FINDINGS
There were no deaths during the course of the study, hence no necropsies were performed.
CLiNICAL SIGNS, SYSTEMIC
No signs of systemic toxicity were observed in the animals.
BODY WEIGHTS
The body weight of the animals was within the range commonly recorded for animals of this strain and age.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Based on the results given in this study, test item failed to cause skin sensitization in the guinea pigs.
- Executive summary:
This study was conducted to assess the cutaneous allergenie potential of FAT 41030/A, the Maximization-Test was performed in 15 (10 test and 5 control) male albino guinea pigs, in accordance with OECD Guideline No. 406. No toxic symptoms were evident in the guinea pigs of the control or test group. No deaths occurred. None of the control and test animals showed skin reactions after the challenge treatment with FAT 41'030/A at 25 % (w/w) in PEG 300.
Based on the above mentioned findings in an adjuvant sensitization test in guinea pigs, FAT 41030/A does not have to be classified and labelled as a skin sensitizer.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.